Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276796 | 0.86 | IMPDH2 (0.44) | IMPDH2IMPDH1CYP19A1CYP2A6MEN1 | |
| SCHEMBL207602 | 0.79 | CYP1A1 (0.36) | IMPDH2IMPDH1 | |
| SCHEMBL29489119 | 0.71 | CYP2A6 (0.54) | IMPDH2IMPDH1CYP19A1CYP2A6CA1 | |
| SCHEMBL1344485 | 0.71 | CYP2A6 (0.54) | IMPDH2IMPDH1CYP19A1CYP2A6CA1 | |
| SCHEMBL91366 | 0.71 | IMPDH2 (1.00) | IMPDH2IMPDH1CYP19A1CYP2A6 | |
| SCHEMBL30389000 | 0.71 | IMPDH2 (1.00) | IMPDH2IMPDH1CYP19A1CYP2A6 | |
| SCHEMBL28194905 | 0.69 | IMPDH2 (0.96) | IMPDH2IMPDH1CYP19A1CYP2A6 | |
| Hydrochloric Acid SCHEMBL27803164 | 0.69 | IMPDH2 (0.96) | IMPDH2IMPDH1CYP19A1CYP2A6 | |
| SCHEMBL29489123 | 0.69 | CYP2A6 (0.52) | IMPDH2IMPDH1CYP19A1CYP2A6CA1 | |
| SCHEMBL1341822 | 0.69 | CYP2A6 (0.52) | IMPDH2IMPDH1CYP19A1CYP2A6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791120-B1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-02-24 | — | — | EP | claimed |
| US-9115121-B2 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | SANOFI (FR) | 2015-08-25 | — | — | US | claimed |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | SANOFI (FR) | 2014-11-20 | — | — | US | claimed |
| EP-2791120-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-22 | — | — | EP | claimed |
| WO-2013087643-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-20 | — | — | WO | claimed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11891386-B2 | Indole compounds and their use | ARIAGEN, INC. (CA) | 2024-02-06 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| US-9115121-B2 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2791120-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013087643-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-20 | — | — | WO | disclosed |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| CN-1738814-A | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| EP-1534281-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004006925-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | IMPDH2 4310/4885IMPDH1 4351/4885CYP19A1 4863/4885 |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | ALK, HRH3, HRH4 | IMPDH2 1563/4885IMPDH1 1719/4885CYP19A1 2135/4885 |
| US-11891386-B2 | Indole compounds and their use | IDO1, IDO2, INMT | IMPDH2 306/4885IMPDH1 434/4885CYP19A1 437/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | IMPDH2 3867/4885IMPDH1 3967/4885CYP19A1 4885/4885 |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ADAM10, ADAM9, CTRL | IMPDH2 2848/4885IMPDH1 2295/4885CYP19A1 376/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | IMPDH2 717/4885IMPDH1 563/4885CYP19A1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.